Skip to main content
Indoco Remedies Ltd. logo

Indoco Remedies Ltd. — Investor Relations & Filings

Ticker · INDOCO ISIN · INE873D01024 LEI · 3358007XE9RRPHJA6U47 BSE.NS Manufacturing
Open in API
Filings indexed 772 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country IN India
Listing BSE.NS INDOCO

About Indoco Remedies Ltd.

https://www.indoco.com/

Indoco Remedies Ltd. is a fully integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of finished dosages and Active Pharmaceutical Ingredients (APIs). The company operates multiple manufacturing facilities equipped to produce various dosage forms, including tablets, capsules, injectables, ophthalmics, and topical preparations. Its therapeutic portfolio spans stomatologicals, anti-infectives, respiratory, cardiovascular, anti-diabetics, and pain management. Indoco maintains a significant global footprint, exporting products to over 55 countries, including highly regulated markets such as the United States and Europe. The organization is recognized for its strong research and development capabilities, focusing on complex generics and niche formulations. Key brands include Sensodent-K, Febrex Plus, and Cyclopam, reflecting its leadership in specific therapeutic segments.

Recent filings

Filing Released Lang Actions
Enclosed the Annual Secretarial Compliance Report dated 13-05-2026 for the Financial Year 2025-2026 issued by our Secretarial auditor CS Ajit Sathe, Proprietor of M/s. A.Y.Sathe & Co, Company ....
Regulatory Filings Classification · 88% confidence The document is titled “Annual Secretarial Compliance Report” prepared by a practicing Company Secretary detailing compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations for the year ended 31 March 2026. It contains no financial statements or substantive quantitative analysis but rather an attestation of statutory and regulatory compliance. Under the “Certification Rule,” such officer attestations and compliance certificates are classified as Regulatory Filings (RNS), not as standalone financial reports or governance policy disclosures.
2026-05-22 English
Intimation regarding completion of transfer of Ophthalmic Division of the Company to Sunways (India) Private Limited
M&A Activity Classification · 91% confidence The document is a formal intimation to stock exchanges about the completion of a slump‐sale transfer of the company's ophthalmic division to another entity, i.e., the closing of a divestiture transaction. This constitutes M&A activity (disposal of a business segment). It is not an earnings release, director dealing, dividend notice, or share issue. Therefore, the correct category is M&A Activity (Code: TAR).
2026-05-18 English
Agreements
M&A Activity Classification · 93% confidence The document is an official stock exchange filing notifying the completion of a business transfer (sale of the ophthalmic division) on a slump sale basis to another company. This is a divestment/transaction event falling under M&A activity announcements. It is not a report of financial results (ER, IR, 10-K), not a board change (MANG), and not merely a publication notice (RPA) but a substantive corporate transaction disclosure. Therefore, it is classified as M&A Activity (TAR).
2026-05-18 English
Demise
Board/Management Information Classification · 95% confidence The document is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) regarding the sad demise and consequent cessation of a Non-Executive Director. This constitutes an announcement of a change in the company’s board of directors, which falls squarely under Board/Management Information (MANG).
2026-05-15 English
The Company hereby regrets to inform about the sad demise of Dr. Anand Nadkarni (DIN : 06881461) Non Executive Director of the Company today i.e. Friday, 15th May, 2026.
Board/Management Information Classification · 90% confidence The document is an official SEBI Regulation 30 disclosure regarding the sad demise (cessation) of a Non-Executive Director, Dr. Anand Nadkarni. It announces a change in the company’s board composition. This clearly falls under “Board/Management Information” (announcement of board changes) rather than a financial report, earnings release, or proxy/material filing.
2026-05-15 English
Press Release
Regulatory Filings Classification · 85% confidence The document is a letter to stock exchanges under SEBI LODR Regulation 30 disclosing the completion of a regulatory inspection and the related press release. It is a material event disclosure, not an earnings release, financial report, or any other specific category. It falls into the general “Regulatory Filings” category for miscellaneous compliance announcements.
2026-05-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.